Laboratory of Medical Microbiology, Yunus Emre State Hospital,
Search for other papers by Elif Aydın in
Current site
Google Scholar
PubMed
Search for other papers by Mustafa Kocaaga in
Current site
Google Scholar
PubMed
Search for other papers by Aybala Temel in
Current site
Google Scholar
PubMed
Abstract
Urinary tract infections are becoming difficult to treat every year due to antibiotic resistance. Uropathogenic Escherichia coli (UPEC) isolates pose a threat with a combined expression of multidrug-resistance and biofilm formation. ST131 clone is a high-risk pandemic clone due to its strong association with antimicrobial resistance, which has been reported frequently in recent years. This study aims to define risk factors, clinical outcomes, and bacterial genetics associated with ST131/O25b UPEC. In this study, antibiotic susceptibility and species-level identification of 61 clinical E. coli strains were determined by automated systems. Detection of extended-spectrum beta-lactamases was assessed by double-disk synergy test. Biofilm formation was quantified by spectrophotometric method. Virulence genes (iutA, sfa cnf-1, iroN, afa, papA, fimA), antibiotic resistance genes (blaCTX-M, blaTEM, blaSHV, blaOXA, qnrA, qnrB, qnrS, ant(2′)-Ia, ant(3)-Ia, aac(3)-IIa, mcr-1, mcr-2, mcr-3, mcr-4) were investigated by PCR. The following beta-lactamase genes were identified, blaTEM (n = 53, 86.8%), blaCTX-M (n = 59, 96.7%), blaSHV (n = 47, 77.0%), and blaOXA-1 (n = 27, 44.2%). Our data revealed that 93.4% of (57/61) E. coli isolates were biofilm-producers. O25pabBspe and trpA2 were investigated for the presence of ST131/O25b clone. Among multidrug resistant isolates, co-existence of O25pabBspe and trpA2 was detected in 29 isolates (47.5%). The fimH30 and H30Rx subclones were detected in four isolates that are strong biofilm-producers. These results suggest that clinical E. coli strains may become reservoirs of virulence and antibiotic resistance genes. This study demonstrates a significant difference in biofilm formation between E. coli ST131 and non-ST131 isolates. Moreover, 86.21% (n = 25) of ST131 isolates produced strong to moderate biofilms, while only 43.75% (n = 14) of non-ST131 isolates showed the ability to form strong biofilms. Presence of iutA and fimA genes in the majority of ST131 strains showed an important role in biofilm formation. These findings suggest application of iutA and fimA gene suppressors in treatment of infections caused by biofilm-producing drug-resistant ST131 strains.
Supplementary Materials
- Supplemental Material
-
1.
Behzadi P, Behzadi E, Pawlak-Adamska EA. Urinary tract infections (UTIs) or genital tract infections (GTIs)? It's the diagnostics that count. GMS Hyg Infect Control 2019; 14: Doc14.
-
2.
Behzadi P, Behzadi E, Yazdanbod H, Aghapour R, Akbari Cheshmeh M, Salehian Omran D. A survey on urinary tract infections associated with the three most common uropathogenic bacteria. Maedica (Bucur) 2010; 5: 111–5.
-
3.
Jahandeh N, Ranjbar R, Behzadi P, Behzadi E. Uropathogenic Escherichia coli virulence genes: invaluable approaches for designing DNA microarray probes. Cent Eur J Urol 2015; 68: 452–8.
-
4.
Behzadi P, Urban E, Gajdacs M. Association between biofilm-production and antibiotic resistance in uropathogenic Escherichia coli (UPEC): an in vitro study. Diseases 2020; 8: 17.
-
5.
Choe HS, Lee SJ, Yang SS, Hamasuna R, Yamamoto S, Cho YH, et al. Summary of the UAA-AAUS guidelines for urinary tract infections. Int J Urol 2018; 25: 175–85.
-
6.
Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med 2012; 366: 1028–37.
-
7.
Neal DE, Jr. Complicated urinary tract infections. Urol Clin North Am 2008; 35: 13–22.
-
8.
Tomas ME, Getman D, Donskey CJ, Hecker MT. Overdiagnosis of urinary tract infection and underdiagnosis of sexually transmitted infection in adult women presenting to an emergency department. J Clin Microbiol 2015; 53: 2686–92.
-
9.
Dason S, Dason JT, Kapoor A. Guidelines for the diagnosis and management of recurrent urinary tract infection in women. Can Urol Assoc J 2011; 5: 316–22.
-
10.
Ramirez-Castillo FY, Moreno-Flores AC, Avelar-Gonzalez FJ, Marquez-Diaz F, Harel J, Guerrero-Barrera AL. An evaluation of multidrug-resistant Escherichia coli isolates in urinary tract infections from aguascalientes, Mexico: cross-sectional study. Ann Clin Microbiol Antimicrob 2018; 17: 34.
-
11.
Aydın E, Cetinkaya S, Koldemir Gündüz M, Koçak Sezgin A. Antimicrobial and antibiofilm effects of melittin and apamin bee venoms from Apis mellifera L. on ESKAPE pathogens and cytotoxic effects on L929 fibroblast cell. Kafkas Univ Vet Fak Derg 2024; 30(4): 559–67.
-
12.
Temel A, Erac B. Investigating biofilm formation and antibiofilm activity using real time cell analysis method in carbapenem resistant acinetobacter baumannii strains. Curr Microbiol 2022; 79: 256.
-
13.
Whelan S, O'Grady MC, Corcoran D, Finn K, Lucey B. Uropathogenic Escherichia coli biofilm-forming capabilities are not predictable from clinical details or from colonial morphology. Diseases 2020; 8: 11.
-
14.
Fang H, Lundberg C, Olsson-Liljequist B, Hedin G, Lindback E, Rosenberg A, et al. Molecular epidemiological analysis of Escherichia coli isolates producing extended-spectrum beta-lactamases for identification of nosocomial outbreaks in Stockholm, Sweden. J Clin Microbiol 2004; 42: 5917–20.
-
15.
Oliver A, Weigel LM, Rasheed JK, McGowan JE Jr., Raney P, Tenover FC. Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli. Antimicrob Agents Chemother 2002; 46: 3829–36.
-
16.
Pagani L, Dell'Amico E, Migliavacca R, D'Andrea MM, Giacobone E, Amicosante G, et al. Multiple CTX-M-type extended-spectrum beta-lactamases in nosocomial isolates of enterobacteriaceae from a hospital in northern Italy. J Clin Microbiol 2003; 41: 4264–9.
-
17.
Celebi D, Aydin E, Rakici E, Baser S, Celebi O, Taghizadehghalehjoughi A. Evaluation of presence of clone ST131 and biofilm formation in ESBL producing and non-producing Escherichia coli strains. Mol Biol Rep 2023; 50: 5949–56.
-
18.
Amin MB, Saha SR, Islam MR, Haider SMA, Hossain MI, Chowdhury A, et al. High prevalence of plasmid-mediated quinolone resistance (PMQR) among E. coli from aquatic environments in Bangladesh. PLoS One 2021; 16: e0261970.
-
19.
Rebelo AR, Bortolaia V, Kjeldgaard JS, Pedersen SK, Leekitcharoenphon P, Hansen IM, et al. Multiplex PCR for detection of plasmid-mediated colistin resistance determinants, mcr-1, mcr-2, mcr-3, mcr-4 and mcr-5 for surveillance purposes. Euro Surveill 2018; 23: 17–00672.
-
20.
Miro E, Grunbaum F, Gomez L, Rivera A, Mirelis B, Coll P, et al. Characterization of aminoglycoside-modifying enzymes in enterobacteriaceae clinical strains and characterization of the plasmids implicated in their diffusion. Microb Drug Resist 2013; 19: 94–9.
-
21.
Guiral E, Bosch J, Vila J, Soto SM. Prevalence of Escherichia coli among samples collected from the genital tract in pregnant and nonpregnant women: relationship with virulence. FEMS Microbiol Lett 2011; 314: 170–3.
-
22.
Arisoy M, Rad AY, Akin A, Akar N. Relationship between susceptibility to antimicrobials and virulence factors in paediatric Escherichia coli isolates. Int J Antimicrob Agents 2008; 31: S4–8.
-
23.
Johnson JR, Stell AL. Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. J Infect Dis 2000; 181: 261–72.
-
24.
Derakhshandeh A, Firouzi R, Motamedifar M, Motamedi Boroojeni A, Bahadori M, Arabshahi S, et al. Distribution of virulence genes and multiple drug-resistant patterns amongst different phylogenetic groups of uropathogenic Escherichia coli isolated from patients with urinary tract infection. Lett Appl Microbiol 2015; 60: 148–54.
-
25.
Usein CR, Damian M, Tatu-Chitoiu D, Capusa C, Fagaras R, Tudorache D, et al. Prevalence of virulence genes in Escherichia coli strains isolated from Romanian adult urinary tract infection cases. J Cell Mol Med 2001; 5: 303–10.
-
26.
Clermont O, Dhanji H, Upton M, Gibreel T, Fox A, Boyd D, et al Rapid detection of the O25b-ST131 clone of Escherichia coli ncompassing the CTX-M-15-producing strains. J Antimicrob Chemother 2009; 64(2): 274–7.
-
27.
Mathers AJ, Peirano G, Pitout JD. Escherichia coli ST131: the quintessential example of an international multiresistant high-risk clone. Adv Appl Microbiol 2015; 90: 109–54.
-
28.
Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011; 66: 1–14.
-
29.
Bayraktar B, Toksoy B, Bulut E. Detection of bla(CTX-M) beta-lactamase genes in extended-spectrum beta-lactamase producing gram-negative bacteria. Mikrobiyol Bul 2010; 44: 187–96.
-
30.
Copur Cicek A, Saral A, Ozad Duzgun A, Yasar E, Cizmeci Z, Ozlem Balci P, et al. Nationwide study of Escherichia coli producing extended-spectrum beta-lactamases TEM, SHV and CTX-M in Turkey. J Antibiot (Tokyo) 2013; 66: 647–50.
-
31.
Yumuk Z, Afacan G, Nicolas-Chanoine MH, Sotto A, Lavigne JP. Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15. J Antimicrob Chemother 2008; 62: 284–8.
-
32.
Aktas E, Otlu B, Erdemir D, Ekici H, Bulut E. A first insight into Escherichia coli st131 high-risk clone among extended-spectrum beta-lactamase-producing urine isolates in istanbul with the use of matrix-assisted laser desorption/ionization time-of-flight mass-spectrometry and real-time pcr. Microb Drug Resist 2017; 23: 1032–6.
-
33.
Can F, Kurt-Azap O, Ispir P, Nurtop E, Seref C, Loclar I, et al. The clinical impact of ST131 H30-Rx subclone in urinary tract infections due to multidrug-resistant Escherichia coli. J Glob Antimicrob Resist 2016; 4: 49–52.
-
34.
Can F, Azap OK, Seref C, Ispir P, Arslan H, Ergonul O. Emerging Escherichia coli O25b/ST131 clone predicts treatment failure in urinary tract infections. Clin Infect Dis 2015; 60: 523–7.
-
35.
Kudinha T, Johnson JR, Andrew SD, Kong F, Anderson P, Gilbert GL. Escherichia coli sequence type 131 as a prominent cause of antibiotic resistance among urinary Escherichia coli isolates from reproductive-age women. J Clin Microbiol 2013; 51: 3270–6.
-
36.
Zhang S, Zhang Q, Huang J, Cao Y, Zhao Z, Li B. Epidemic potential of Escherichia coli O16:H41-ST131: compared with pandemic O25b:H30-ST131 lineage. Infect Drug Resist 2021; 14: 2625–32.
Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary
Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu
Indexing and Abstracting Services:
- Biological Abstracts
- BIOSIS Previews
- CAB Abstracts
- CABELLS Journalytics
- Chemical Abstracts
- Global Health
- Index Medicus
- Index Veterinarius
- Medline
- Referativnyi Zhurnal
- SCOPUS
- Science Citation Index Expanded
| 2023 | |
|---|---|
| Web of Science | |
| Journal Impact Factor | 1.3 |
| Rank by Impact Factor | Q4 (Immunology) |
| Journal Citation Indicator | 0.31 |
| Scopus | |
| CiteScore | 2.3 |
| CiteScore rank | Q3 (Infectious Diseases) |
| SNIP | 0.389 |
| Scimago | |
| SJR index | 0.308 |
| SJR Q rank | Q3 |
| Acta Microbiologica et Immunologica Hungarica | |
|---|---|
| Publication Model | Hybrid |
| Submission Fee | none |
| Article Processing Charge | 1100 EUR/article (only for OA publications) |
| Regional discounts on country of the funding agency | World Bank Lower-middle-income economies: 50% World Bank Low-income economies: 100% |
| Further Discounts | Editorial Board / Advisory Board members: 50% Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100% |
| Subscription fee 2025 | Online subsscription: 772 EUR / 848 USD Print + online subscription: 860 EUR / 944 USD |
| Subscription Information | Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content. |
| Purchase per Title | Individual articles are sold on the displayed price. |
| Acta Microbiologica et Immunologica Hungarica | |
|---|---|
| Language | English |
| Size | A4 |
| Year of Foundation |
1954 |
| Volumes per Year |
1 |
| Issues per Year |
4 |
| Founder | Magyar Tudományos Akadémia |
| Founder's Address |
H-1051 Budapest, Hungary, Széchenyi István tér 9. |
| Publisher | Akadémiai Kiadó |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| ISSN | 1217-8950 (Print) |
| ISSN | 1588-2640 (Online) |
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Jun 2024 | 0 | 0 | 0 |
| Jul 2024 | 2080 | 11 | 9 |
| Aug 2024 | 2665 | 1 | 2 |
| Sep 2024 | 247 | 4 | 6 |
| Oct 2024 | 370 | 4 | 5 |
| Nov 2024 | 248 | 0 | 0 |
| Dec 2024 | 25 | 0 | 0 |
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.